Atopic Dermatitis

Phase 3 open-label extension data suggest young patients may even improve skin clearance scores after a year on the biologic therapy.

A review of the safety and efficacy of systemic agents such as methotrexate, azathioprine, and cyclosporine in patients with severe, persistent atopic dermatitis.

Experts in the management of atopic dermatitis review the safety and efficacy of topical calcineurin inhibitors and topical PDE4 inhibitors.

According to objective and subjective measures, children with more severe atopic dermatitis were more likely to report a learning disability.

Initial rates of common treatment-emergent adverse events from baricitinib 2 mg appear to remain stable or decrease with prolonged exposure.

Peter Lio, MD, and Elizabeth Swanson, MD, provide insight on using nonpharmacological therapies and state-of-the-art skin care treatments for patients with atopic dermatitis.

Patient factors considered when prescribing treatment options for the management of atopic dermatitis.

Some strains appear to reduce risk in pregnant women and infants.

A dermatologist discusses alternative and complementary options for the treatment of atopic dermatitis.

A dermatologist gives a broad overview of key considerations when determining a treatment course for pediatric patients.

Reviewing the importance of newer models of collaboration between specialty and primary care for atopic dermatitis and educating patients and caregivers for disease management.

Lawrence F. Eichenfield, MD; Jeffrey M. Bienstock, MD, FAAP; Peter A. Lio, MD; and Elizabeth A. Swanson, MD, discuss the importance of an integrative approach to care for the management of atopic dermatitis.

The oral Janus kinase 1 inhibitor abrocitinib produced similar outcomes to dupilumab in a placebo-controlled comparison for atopic dermatitis.

The pandemic forced practices to consider more virtual screening and care. A dermatologist shares perspective on what's been working as telemedicine practice.

Elizabeth Swanson, MD, leads the discussion on emerging data on comorbid conditions associated with atopic dermatitis and management in the clinical setting.

An expert offers his perspective on the investigative SLP receptor modulator for atopic dermatitis.

An expert discusses new and emerging therapies for atopic dermatitis.

A dermatologist discusses some of her most common cosmetic practices and techniques.

Lawrence F. Eichenfield, MD; Jeffrey M. Bienstock, MD, FAAP; Peter A. Lio, MD; and Elizabeth A. Swanson, MD, discuss whether children outgrow atopic dermatitis and advice for the management of disease.

The role of multidisciplinary management in diagnosing atopic dermatitis and when patients typically seek care.

Jeffrey Bienstock, MD, FAAP, identifies the various triggers causing flare-ups for atopic dermatitis in patients.

Treatment showed a similar effect on patients with and without baseline asthma.